US Fibroscan market Research Report By Technology (Vibration-controlled Transient Electrography (VCTE), Controlled Attenuation Parameter (CAP), Others), By Modality (Portable, Non-Portable/Standalone), By Application (Hepatitis B or C, Non-alcoholic Fatty Liver Disease, Alcohol-related Liver Problems, Hemochromatosis, Others) and By End-user (Hospitals & Clinics, Diagnostic Centers, Ambulatory Surgical Centers, Others) - Forecast to 2035

US Fibroscan market Overview

As per MRFR analysis, the US Fibroscan Market Size was estimated at 19.55 (USD Billion) in 2024.The US Fibroscan market Industry is expected to grow from 22.85(USD Billion) in 2025 to 37 (USD Billion) by 2035. The US Fibroscan Market CAGR (growth rate) is expected to be around 4.479% during the forecast period (2025 - 2035)

Key US Fibroscan Market Trends Highlighted

The US Fibroscan market is experiencing notable growth driven by several key market drivers. The increasing prevalence of liver diseases, such as non-alcoholic fatty liver disease (NAFLD) and hepatitis, is pushing healthcare providers to adopt advanced diagnostic tools. Additionally, there is a growing awareness among physicians and patients about the importance of early diagnosis and monitoring of liver conditions, contributing to a higher demand for non-invasive diagnostic technologies like Fibroscan. This trend is further supported by initiatives from various public health organizations aimed at health education and outreach regarding liver health.

Opportunities for capture in the US Fibroscan market include the expansion of Fibroscan technology in rural and underserved areas, where access to specialized liver care is often limited. Moreover, the integration of Fibroscan with telemedicine platforms could enhance patient monitoring and follow-up services, thus opening new channels for patient engagement and increased testing. As insurance coverage for such diagnostic procedures evolves, patients will likely have greater access, stimulating market growth. Recent trends in the sector indicate a shift towards personalized medicine, wherein treatment plans are tailored to the unique needs of patients based on Fibroscan results.

The technology's ability to provide real-time liver stiffness measurements has positioned it as a preferred method among clinicians looking for accurate assessments without invasive procedures. Furthermore, collaborations between technology companies and healthcare providers are emerging, focused on refining and enhancing the capabilities of Fibroscan devices, ensuring they meet the clinical diagnostic needs of today.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

US Fibroscan market Drivers

Rising Prevalence of Liver Diseases

The increasing incidence of liver diseases, particularly non-alcoholic fatty liver disease (NAFLD) and viral hepatitis, is a significant driver for the growth of the US Fibroscan Market Industry. According to the Centers for Disease Control and Prevention (CDC), approximately 4.5 million people in the United States have liver conditions, which have been rising by about 3% annually over the past decade. Organizations such as the American Liver Foundation play a pivotal role in raising awareness and advocating for early diagnosis and treatment of liver diseases, thereby driving demand for advanced diagnostic tools such as Fibroscan.

Healthcare practitioners are now adopting Fibroscan technology in clinical settings due to supporting guidelines from the Food and Drug Administration, which allow non-invasive approaches to liver assessment.

Technological Advancements in Fibroscan Devices

Innovations in Fibroscan technology, including improved accuracy and user-friendliness, are propelling the US Fibroscan Market Industry forward. Recent advancements in elastography techniques have increased the precision of liver stiffness measurements, attracting healthcare providers to adopt these devices. A report from the American Association for the Study of Liver Diseases indicates that the accuracy of Fibroscan for diagnosing significant liver fibrosis has improved to around 90% with the latest technology.

Major players in the market are continually investing in Research and Development (R&D) for these advancements, making Fibroscan a critical tool for liver health assessment in the US.

Increasing Awareness of Preventive Healthcare

The growing emphasis on preventive healthcare measures is significantly boosting the demand for non-invasive diagnostic tools like Fibroscan in the US Fibroscan Market Industry. Public health initiatives by organizations like the CDC emphasize the importance of early diagnosis and lifestyle modifications in preventing chronic diseases, including liver conditions. Data shows that approximately 65% of adults in the US engage in health screenings, an increase from previous years, leading to higher usage of liver assessment tools.

This rise in awareness and the adoption of preventive healthcare practices create a favorable environment for Fibroscan technology.

Regulatory Support and Healthcare Reimbursement Policies

Supportive regulatory frameworks and reimbursement policies for innovative medical devices positively influence the growth of the US Fibroscan Market Industry. Recent changes in Medicare reimbursement policies have expanded coverage for non-invasive liver assessment methods, making Fibroscan more accessible to a broader patient population. The increase in insurance coverage by major providers has led to a rise in patient screenings for liver diseases, demonstrating a significant increase in the adoption of this technology.

This regulatory support ensures that both healthcare providers and patients see the value in using Fibroscan for the early detection and management of liver diseases.

US Fibroscan market Segment Insights

Fibroscan Market Technology Insights

The US Fibroscan Market focuses on advanced technologies that enhance the assessment of liver health, primarily through tools based on techniques like Vibration-controlled Transient Elastography (VCTE) and Controlled Attenuation Parameter (CAP). The growth of the market is underpinned by increasing cases of liver diseases, driven by factors such as obesity and viral hepatitis. The technology segment plays a pivotal role in delivering accurate and non-invasive assessments, thus meeting the rising demand for efficient liver evaluation methods within the healthcare system.

VCTE remains significant due to its ability to provide precise measurements of liver stiffness, thereby assisting healthcare providers in diagnosing conditions like fibrosis. CAP technology is essential for measuring liver fat content, making it crucial in evaluating non-alcoholic fatty liver disease, which has become more prevalent in the United States. These innovations reflect a growing trend toward non-invasive diagnostic methods in the medical field, facilitating quicker clinical decisions and improving patient experiences. Additionally, ongoing Research and Development efforts in this area are exploring ways to combine these technologies further, enhancing their sensitivity and specificity.

The demand for advanced technologies in liver assessment presents opportunities for growth in the US Fibroscan Market, propelling forward innovations and enabling better patient management strategies. Overall, the technology segment is positioned to significantly influence the landscape of liver disease diagnosis and management in the US, emphasizing the importance of continual advancements and their integration within healthcare practices.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Fibroscan Market Modality Insights

The US Fibroscan Market, particularly focusing on the Modality segment, is experiencing noteworthy dynamics driven by advancements in diagnostic technologies and patient care requirements. The market is primarily divided into Portable and Non-Portable/Standalone modalities, each offering distinct advantages. Portable Fibroscan devices are increasingly significant due to their flexibility, enhancing accessibility in various healthcare settings such as outpatient clinics and rural health facilities, which are vital in the vast US healthcare landscape.

This adaptability fosters increased patient throughput and improves overall diagnostic efficiency. Meanwhile, Non-Portable/Standalone devices dominate larger healthcare institutions owing to their advanced features and capabilities, making them essential for comprehensive liver assessment in specialized settings. Trends such as an increasing focus on non-invasive procedures, coupled with the need for timely liver disease diagnoses, are propelling market growth. However, challenges such as high initial costs and the requirement for trained professionals to operate sophisticated devices remain pertinent.

Overall, as the awareness around liver diseases rises in the US, these modalities will likely play pivotal roles in enhancing healthcare delivery and patient outcomes. The ongoing Research and Development in the Fibroscan Market will further support both modalities by introducing innovative technologies to meet evolving market needs.

Fibroscan Market Application Insights

The Application segment of the US Fibroscan Market plays a crucial role in diagnosing and managing liver diseases, serving a diverse patient demographic with various conditions. Key applications within this segment include Hepatitis B or C, which remain persistent health concerns in the US, affecting millions. Non-alcoholic Fatty Liver Disease has gained increasing attention due to rising obesity rates, making it a significant focus for the market. Also noteworthy are Alcohol-related Liver Problems, which highlight the importance of understanding lifestyle-related liver conditions in public health strategies.

Hemochromatosis, a hereditary disorder, is another vital area, emphasizing the need for targeted diagnostic technologies. Other applications encompass a variety of liver diseases, demonstrating the broad scope of the Fibroscan utility. The projected growth of this market indicates an expanding awareness of liver health, alongside improving technology, which enhances diagnosis capabilities, ultimately driving growth and innovation within the US Fibroscan Market. As healthcare providers and patients increasingly prioritize early diagnosis and treatment options, the demand for advanced fibroscan applications is expected to rise.

Fibroscan Market End-user Insights

The End-user segment of the US Fibroscan Market showcases a diverse landscape driven by various healthcare providers, each playing a significant role in service delivery. Hospitals and Clinics constitute a large share of this segment, offering comprehensive services and advanced diagnostic capabilities, which makes them crucial in patient management. Diagnostic Centers are also essential as they focus on specialized testing and provide timely results, catering to a growing number of patients with liver-related health issues. Additionally, Ambulatory Surgical Centers are noteworthy for their efficiency in performing outpatient procedures related to fibrotic diseases, enhancing patient convenience and reducing healthcare costs.

Other facilities encompass a range of healthcare settings, including community health clinics and private practices that contribute to accessibility and patient outreach for Fibroscan services. This segmentation reflects the increasing awareness and demand for non-invasive liver diagnostics, as well as the ongoing advancements in technology and treatment modalities that continue to shape the US Fibroscan Market dynamics. The integration of innovative solutions across these End-user categories presents substantial opportunities for growth and improves patient outcomes across the healthcare spectrum.

US Fibroscan market Key Players and Competitive Insights

The US Fibroscan Market has been experiencing significant growth and transformation as companies strive to meet the increasing demand for non-invasive and accurate diagnostic tools for liver diseases. The competition in this sector is marked by innovation, technological advancements, and strategic partnerships aimed at broadening market access and enhancing product offerings. With the prevalence of liver conditions on the rise, particularly non-alcoholic fatty liver disease, firms in the market are focused on improving patient outcomes through better diagnostic solutions. This landscape is further shaped by regulatory developments, reimbursement policies, and the need for companies to adapt to evolving customer needs and healthcare trends.

Fujifilm Holdings Corporation has established a robust presence in the US Fibroscan Market through its commitment to innovation and quality. The company specializes in developing advanced imaging technologies that enhance the accuracy of liver assessments. Fujifilm's strengths lie in its comprehensive research and development initiatives, which enable the company to stay ahead of market trends and deliver cutting-edge solutions. By utilizing its extensive expertise in medical imaging, Fujifilm has successfully created FibroScan devices that are user-friendly and effective in diagnosing liver conditions. The company's focus on education and training for healthcare professionals further solidifies its reputation as a trusted leader in the US market.

In the landscape of the US Fibroscan Market, Boston Scientific stands out due to its innovative approaches and a strong portfolio of diagnostic solutions. The company is recognized for providing a range of advanced medical devices tailored to the specific needs of healthcare providers in the field of gastroenterology and hepatology. Boston Scientific's commitment to developing products that enhance patient care is evident in their offerings, which often include tools for minimally invasive procedures alongside Fibroscan technologies. Their strategic mergers and acquisitions have enabled them to expand their market presence and capabilities in liver diagnostics. Boston Scientific continually invests in research and development, which strengthens its position in the US market by allowing the company to deliver state-of-the-art solutions that align with the evolving demands of healthcare professionals and patients.

Key Companies in the US Fibroscan Market Include

• Fujifilm Holdings Corporation


• Boston Scientific


• Echosens


• Siemens Healthineers


• Sonic Technologies


• GE Healthcare


• Abbott Laboratories


• Boehringer Ingelheim


• Medtronic


• Merck Group


• Novartis


• CITC


• MediCircles


• Philips Healthcare

US Fibroscan market Industry Developments

The US Fibroscan Market has seen notable developments recently, driven by technological advancements and increased demand for non-invasive diagnostic tools in hepatology. Companies such as Fujifilm Holdings Corporation, Echosens, and Siemens Healthineers are expanding their service portfolios to enhance liver disease diagnostics. In October 2023, it was reported that Boston Scientific entered into a strategic partnership to improve Fibroscan-related technologies, solidifying its position in the market. Additionally, there have been increased valuations for firms involved in liver health, reflecting a broader trend towards preventive healthcare.

The growing prevalence of liver-related diseases in the US, coupled with an increasing focus on early detection and intervention strategies, continues to drive market growth. Historical milestones include the 2021 FDA approval of enhanced Fibroscan devices, which significantly contributed to market penetration. While recent mergers and acquisitions specifically involving these companies have not been prominent, the landscape remains dynamic, with ongoing investments being made to advance Research and Development efforts in liver diagnostics. The intersection of innovation and a rising awareness of liver health is propelling the evolution of the US Fibroscan Market, warranting further scrutiny.

Fibroscan Market Segmentation Insights

• Fibroscan Market Technology Outlook
  
  
  
  • Vibration-controlled Transient Electrography (VCTE)
  
  
  • Controlled Attenuation Parameter (CAP)
  
  
  • Others 
  
  
  
  


• Fibroscan Market Modality Outlook
  
  
  
  • Portable
  
  
  • Non-Portable/Standalone 
  
  
  
  


• Fibroscan Market Application Outlook
  
  
  
  • Hepatitis B or C
  
  
  • Non-alcoholic Fatty Liver Disease
  
  
  • Alcohol-related Liver Problems
  
  
  • Hemochromatosis
  
  
  • Others
  
  
  
  


• Fibroscan Market End-user Outlook
  
  
  
  • Hospitals & Clinics
  
  
  • Diagnostic Centers
  
  
  • Ambulatory Surgical Centers
  
  
  • Others
  
  
  
  

Report Attribute/Metric	Details
Market Size 2024	19.55(USD Billion)
Market Size 2025	22.85(USD Billion)
Market Size 2035	37.0(USD Billion)
Compound Annual Growth Rate (CAGR)	4.479% (2025 - 2035)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Base Year	2024
Market Forecast Period	2025 - 2035
Historical Data	2019 - 2024
Market Forecast Units	USD Billion
Key Companies Profiled	Fujifilm Holdings Corporation, Boston Scientific, Echosens, Siemens Healthineers, Sonic Technologies, GE Healthcare, Abbott Laboratories, Boehringer Ingelheim, Medtronic, Merck Group, Novartis, CITC, MediCircles, Philips Healthcare
Segments Covered	Technology, Modality, Application, End-user
Key Market Opportunities	Increased liver disease prevalence, Adoption of non-invasive testing, Aging population demand, Technological advancements in imaging, Expanding healthcare reimbursement policies
Key Market Dynamics	Increasing prevalence of liver diseases, Advancements in non-invasive diagnostics, Growing awareness and education, Rising healthcare expenditures, Technological innovations in imaging
Countries Covered	US